Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nevada for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nevada only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nevada (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Christianne Yung (NPI 1205862497)

Field	Value
Entity Type	Individual
Organization	Christianne Yung
Address	2482 West Horizon Ridge Pkwy
City	Henderson
State	NV
ZIP	89052
Taxonomy	Rheumatology Physician
NPI Enumerated	June 23, 2006

Payer Source	Total Paid
Medicare	$2.1M
Medicaid	$0

Key Findings

This profile is essentially Medicare-only: total Medicare revenue is $2.1M while there is no Medicaid billing on file, so payer exposure is concentrated entirely in Medicare for the claims available. That concentration means any network or reimbursement changes from Medicare will disproportionately affect this provider's revenue base.

Revenue is highly concentrated in a small set of biologic/injectable drugs: the top 3 Medicare codes by revenue account for 61.5% of this provider's total Medicare revenue, led by J3111 at $532.6K (25.6%), J0897 at $404K (19.5%), and J1745 at $341.2K (16.4%). These three products alone generate the majority of billings, indicating the practice’s financial model is driven by high-cost therapeutics rather than office visits.

The CPT/HCPCS mix is consistent with a rheumatology practice that runs an in-office infusion and injection service: leading codes are injectable biologics (J3111, J0897, J1745) and other administration/infusion codes appear throughout the top items, including 96413 (403 claims, $39.9K, 1.9%), 96365 (114 claims, $5.9K, 0.3%), and 96415 (487 claims, $10.2K, 0.5%). Multiple disease-modifying biologics such as J0129 (abatacept, $301.8K, 14.5%) and J0717 (certolizumab pegol, $290.4K, 14.0%) further support the view that the practice focuses on in-office biologic therapy for chronic immune-mediated conditions.

On national competitive standing for the largest drugs, this provider ranks well above typical volume: J3111 ranks #38 of 970 (96th percentile; notably above typical national volume), J0897 ranks #219 of 10057 (98th percentile; notably above typical national volume), and J1745 ranks #42 of 1352 (97th percentile; notably above typical national volume). These percentile positions indicate the provider is a major national-volume participant for these specific injectables rather than a modest user.

Several procedure and infusion codes register as statistical outliers versus national peers: 96372 is marked as an extreme outlier (rank #115 of 58224, 100th percentile), and 96415 is similarly an extreme outlier (rank #71 of 4959, 99th percentile), while 96413 sits at the 85th percentile. Together with a high-rank 99214 (977 claims, $89.9K, 4.3%; rank #12094 of 479517, 97th percentile), the pattern shows unusually large volumes of infusion/injection activity and relatively elevated office visit volumes for a specialist practice.

There is a clear bone-health / osteoporosis treatment signal in the mix: J3111 (romosozumab, $532.6K, 25.6%) and J0897 (denosumab, $404K, 19.5%) are the two largest revenue contributors and the profile also includes DXA codes 77085 ($9.8K, 0.5%) and 77080 ($1.3K, 0.1%). This combination of high-volume osteoporosis agents and DXA imaging suggests the practice prioritizes pharmacologic and diagnostic services for bone disease management alongside rheumatologic care.

The provider has long tenure in the NPI registry (enumerated 2006-06-23, ~20 years ago), which supports interpretation of these billing patterns as an established operational model rather than a recent practice change. That longevity may also reflect an embedded referral and administration infrastructure needed to sustain high volumes of biologic administration.

From a contracting and risk perspective, the practice’s dependence on high-cost injectable drugs and Medicare as the sole payer on file creates exposure concentrated in drug reimbursement and Medicare policy changes; routine E/M visits generate a small share of revenue compared with drugs (99214 is $89.9K, 4.3% of Medicare revenue) while biologic codes dominate income. Payors evaluating network value should consider the provider’s unusually large administration volumes and high national percentiles for specific biologics when negotiating reimbursement or designing utilization management for these products.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

29 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J3111	Injection, romosozumab-aqqg, 1 mg	66,570	$10	$532.6K
J0897	Injection, denosumab, 1 mg	22,440	$20	$404K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	13,120	$30	$341.2K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	8,880	$30	$301.8K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	72,600	$1	$290.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	980	$90	$89.9K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	400	$100	$39.9K
96372	A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician…	1,590	$10	$17.5K
96415	In this add on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report each additional hour of infusion beyond the…	490	$20	$10.2K
77085	The provider measures the mineral density of the bones of the axial skeleton and assesses a vertebral fracture. He performs the procedure to assess the patient for the presence of osteoporosis or…	190	$50	$9.8K

Showing 1–10 of 29

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 29 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nevada Distribution

Christianne Yung — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nevada

Full comparison — all codes billed, vs. state median

29 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J3111	2	10	67,100	$10	$528K
J0129	2	10	8,300	$30	$297.2K
J0717	3	10	72,600	$1	$247.5K
J1745	1	10	8,960	$30	$231.9K
J0897	2	70	3,630	$20	$94.6K
96413	13	70	210	$100	$23.7K
99214	123	3,610	110	$80	$19K
99213	1,446	3,500	80	$60	$10K
96365	41	90	110	$50	$9.7K
96401	17	30	100	$60	$7.1K

Showing 1–10 of 29

Nearby Providers

Other providers in the same ZIP code as Christianne Yung, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Platinum Hospitalists LLP	NV	Hospitalist Physician	$0	$38.8M
Urgent Care Nevada, LLC	NV	Urgent Care Clinic/Center	$0	$34.9M
Dignity Health	NV	General Acute Care Hospital	$0	$18.7M
Behavioral Health Solutions LLC	NV	Community/Behavioral Health Agency	$0	$11.4M
Lamotte Pediatrics, LLP	NV	Pediatrics Physician	$0	$9.4M
Minghsun Liu Md PC	NV	Infectious Disease Physician	$0	$5.1M
Optimized Management LLC	NV	Clinical Social Worker	$0	$5M
Misch/hyun/hodapp Healthcare, LLP	NV	Pediatrics Physician	$0	$4.5M
Ellsworth Cox Pediatric Dentistry LLC	NV	Pediatric Dentistry	$0	$3.7M
Total Infusion Care LLC	NV	Home Infusion Therapy Pharmacy	$0	$3.1M

Christianne Yung — Billing Profile & Reimbursement Data

Sign up for Christianne Yung — Billing Profile & Reimbursement Data policy alerts

Christianne Yung — Billing Profile & Reimbursement Data

Sign up for Christianne Yung — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Nearby Providers

Frequently Asked Questions

References